MAPT and glaucoma: Interestingly, in a previous report, Nucci et al. [5] described a glaucoma patient with medically controlled IOP who experienced disease progression concomitantly with the onset of mild cognitive impairment and positivity for CSF markers of AD (decreased amyloid-beta 42 (Aβ42) and elevated levels of t-tau and phosphorylated tau).